Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.43 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.42 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11400102 | 0.98 | EGFR (0.45) | EGFRERBB2CA12CA2CA9 | |
| SCHEMBL11054906 | 0.90 | EGFR (0.41) | EGFRERBB2CA12CA2CA9 | |
| SCHEMBL3725117 | 0.86 | TAAR1 (0.44) | EGFRERBB2CA12CA2CA9 | |
| SCHEMBL11044440 | 0.85 | CA12 (0.50) | CA12CA2CA9TAAR1HTT | |
| SCHEMBL11414547 | 0.84 | EGFR (0.40) | EGFRERBB2CA12CA2CA9 | |
| SCHEMBL7389171 | 0.83 | SIGMAR1 (0.44) | EGFRERBB2CA12CA2CA9 | |
| SCHEMBL11145951 | 0.80 | CA12 (0.47) | CA12CA2CA9TAAR1HTT | |
| SCHEMBL13645984 | 0.80 | SIGMAR1 (0.48) | CA12CA2CA9TAAR1HTT | |
| SCHEMBL31135311 | 0.80 | CA12 (0.47) | EGFRERBB2CA12CA2CA9 | |
| SCHEMBL11050700 | 0.79 | ALDH1A1 (0.48) | EGFRERBB2SLC22A2SLC22A3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117486761-A | Aryl-containing chloroethyl nitrosourea compound and preparation method and application thereof | 南方医科大学 | 2024-02-02 | — | — | CN | disclosed |
| EP-2819993-B1 | ROS-ACTIVATED COMPOUNDS AS SELECTIVE ANTI-CANCER THERAPEUTICS | UNIV CINCINNATI (US) | 2020-09-02 | — | — | EP | disclosed |
| US-9394233-B2 | ROS-activated compounds as selective anti-cancer therapeutics | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2016-07-19 | — | — | US | disclosed |
| CN-105017090-A | 4-(N-methyl-N-sulfoethyl)aminobenzaldehyde sodium salt synthesis method | TIANCHANG TIANJIA CHEMICAL TECHNOLOGY CO LTD | 2015-11-04 | — | — | CN | disclosed |
| EP-2819993-A1 | ROS-ACTIVATED COMPOUNDS AS SELECTIVE ANTI-CANCER THERAPEUTICS | University Of Cincinnati (US) | 2015-01-07 | — | — | EP | disclosed |
| WO-2013130968-A1 | ROS-ACTIVATED COMPOUNDS AS SELECTIVE ANTI-CANCER THERAPEUTICS | UNIVERSITY OF CINCINNATI (US) | 2013-09-06 | — | — | WO | disclosed |
| US-20130230542-A1 | ROS-Activated Compounds as Selective Anti-Cancer Therapeutics | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2013-09-05 | — | — | US | disclosed |
| US-RE38416-E1 | NUCLEOTIDE BASES COMPRISING PYRAZOLO(3,4-D)PYRIMIDINES USED FOR MEDICAL DIAGNOSIS, THERAPY, HYBRIDIZATION, ANTISENSE AGENTS OR REPORTER MOLECULES | EPOCH BIOSCIENCES, INC. | 2004-02-03 | — | — | US | disclosed |
| WO-2001092285-A1 | NOVEL OLIGONUCLEOTIDE COMPOUNDS HAVING PYRROLIZINE DERIVATIVES, PROCESSES FRO PREPARING THEM, COMPOSITIONS CONTAINING THEM AND USES THEREOF IN TREATMENT, DIAGNOSIS AND ANALYSIS OF GENE-RELATED DISEASES | GENECHEM INC. (KR) | 2001-12-06 | — | — | WO | disclosed |
| US-6312953-B1 | MODIFIED OLIGONUCLEOTIDE COMPLEMENTARY TO A TARGET SEQUENCE AND HAVING AT LEAST TWO CROSSLINKING AGENTS COVALENTLY ATTATCHED; GENE EXPRESSION INHIBITION; DNA SEQUENCING; GENETIC MAPPING | EPOCH PHARMACEUTICALS, INC. | 2001-11-06 | — | — | US | disclosed |
| US-5849482-A | Crosslinking oligonucleotides | EPOCH PHARMACEUTICALS, INC. (US) | 1998-12-15 | — | — | US | disclosed |
| US-5824796-A | MEDICAL DIAGNOSIS WITH TARGET DNA OR RNA FOR ENZYME INHIBITORS | EPOCH PHARMACEUTICALS, INC. (US) | 1998-10-20 | — | — | US | disclosed |
| EP-0842186-A1 | CROSS-LINKING OLIGONUCLEOTIDES | MICROPROBE CORPORATION (US) | 1998-05-20 | — | — | EP | disclosed |
| WO-1996040711-A1 | CROSS-LINKING OLIGONUCLEOTIDES | MICROPROBE CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1994017092-A1 | BIFUNCTIONAL CROSSLINKING OLIGONUCLEOTIDES ADAPTED FOR LINKING TO A DESIRED GENE SEQUENCE OF INVADING ORGANISM OR CELL | MICROPROBE CORPORATION (US) | 1994-08-04 | — | — | WO | disclosed |
| US-4439380-A | Photopolymerizable composition, especially for dental purposes | ETABLISSEMENT DENTAIRE IVOCLAR (LI) | 1984-03-27 | — | — | US | disclosed |
| US-4115413-A | ACID FREE | BAYER AKTIENGESELLSCHAFT (DE) | 1978-09-19 | — | — | US | disclosed |
| US-4059402-A | SUBLIMATION, MONOAZO DYES | BAYER AKTIENGESELLSCHAFT (DT) | 1977-11-22 | — | — | US | disclosed |
| US-3963747-A | Basic arylmercaptonaphtholactam dyes | BASF AKTIENGESELLSCHAFT (DT) | 1976-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130230542-A1 | ROS-Activated Compounds as Selective Anti-Cancer Therapeutics | ROS1, NOX4, NOX1 | EGFR 140/4885ERBB2 248/4885CA12 3227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.